Effects of Brexit: The Paul-Ehrlich-Institut is making preparations
After the Brexit the UK's agencies for human and veterinary medicines (Medicines and Healthcare Products Regulatory Agency, MHRA and Veterinary Medicines Directorate, VMD) will probably no longer be available for EU marketing authorisation procedures. Product testing and issuing EU certificates for official batch releases are also affected by the Brexit.
Langener Nachwuchswissenschaftspreis (Langen Prize for Junior Scientists) 2018 awarded for biomedical research
The Paul-Ehrlich-Institut (PEI) and the Verein zur Förderung des Langener Wissenschaftspreises (Association for the Promotion of the Langen Science Prize) have awarded the Langen Prize for Junior Scientists for the seventh time. Three young scientists convinced the jury of their excellent research performance in biomedicine.
Biomedicine is booming
Antibodies, cell and gene therapeutics, and other biomedicines account for 35 percent of all clinical trials for which applications have been submitted, and this rate is increasing.
"With its advisory services in regulatory affairs, the PEI contributes to a continued optimisation of development periods up to the marketing authorisation and assures that biomedicines in Germany and Europe are safe and effective", explained Professor Klaus Cichutek, president of the PEI.